Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan

• Published in: Scientific reports Vol. 11; no. 1; p. 5802
• Main Authors: Hsu, Yin-Chen, Yu, Chih-Hsiang, Chen, Yan-Ming, Roberts, Kathryn G., Ni, Yu-Ling, Lin, Kai-Hsin, Jou, Shiann-Tarng, Lu, Meng-Yao, Chen, Shu-Huey, Wu, Kang-Hsi, Chang, Hsiu-Hao, Lin, Dong-Tsamn, Lin, Shu-Wha, Lin, Ze-Shiang, Chiu, Wei-Tzu, Chang, Chia-Ching, Ho, Bing-Ching, Mullighan, Charles G., Yu, Sung-Liang, Yang, Yung-Li
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.03.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67/1990; 631/67/2332; Acute lymphoblastic leukemia; Children; Clinical trials; Genomics; Heavy chains; Humanities and Social Sciences; Immunoglobulins; Leukemia; Lymphocytes B; multidisciplinary; Philadelphia chromosome; Polymerase chain reaction; Protein-tyrosine kinase; Reverse transcription; Science; Science (multidisciplinary); Taiwan
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-85213-6

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukaemia (ALL), a high-risk subtype characterised by genomic alterations that activate cytokine receptor and kinase signalling, is associated with inferior outcomes in most childhood ALL clinical trials. Half of the patients with Ph-like ALL have kinase rearrangements or fusions. We examined the frequency and spectrum of these fusions using a retrospective cohort of 212 newly diagnosed patients with childhood B-cell ALL. Samples without known chromosomal alterations were subject to multiplex reverse transcription polymerase chain reaction to identify known Ph-like kinase fusions. Immunoglobulin heavy chain locus (IGH) capture and kinase capture were applied to samples without known kinase fusions. We detected known kinase fusions in five of 212 patients, comprising EBF1-PDGFRB, ETV6-ABL1, ZC3HAV1-ABL2, EPOR-IGH , and CNTRL-ABL1 . Two patients with P2RY8-CRLF2 were identified. Patients with non-Ph kinase fusions had inferior 5-year event-free survival and overall survival compared with patients with other common genetic alterations. The prevalence of non-Ph kinase fusions in our Taiwanese cohort was lower than that reported in Caucasian populations. Future clinical trials with tyrosine kinase inhibitors may be indicated in Taiwan because of the inferior outcomes for B-cell ALL with kinase fusions.